Author

Aniruddha Sarkar

Brigham and Women's HospitalORCID 0000-0002-9393-1335Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Aniruddha Sarkar1 paper · Harvard University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander SpektoriD· 1 shared Andrew T. BockusiD· 1 shared Benedikt Mathias KessleriD· 1 shared Bernard Levin· 1 shared Bishma TuladhariD· 1 shared Breena Fraga-Walton· 1 shared Bryan M. Lent· 1 shared Catherine E. GleasoniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander SpektorORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyJournal of Thoracic OncologyPeer-reviewedAug 1, 2025

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

Shilpa Singh, Catherine E. Gleason, Min Fang…·Matthew G. Oser

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

29 citationstop 1%

humanproteomics

𝕏 PostBluesky